Biocon Biologics Gets USFDA Approval For Cancer Biosimilar

FDA Approves Biocon Biologics’ Bevacizumab Biosimilar

On April 10, 2025, Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE (bevacizumab-nwgd), a new bevacizumab biosimilar referencing Genentech’s AVASTIN®.  JOBEVNE is a recombinant humanized monoclonal antibody that acts as a vascular endothelial growth factor inhibitor.  It is indicated for the treatment of certain types of colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma,…

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

Biocon Biologics has received approval from the US Food and Drug Administration for the intravenous use of Jobevne (bevacizumab-nwgd).

Bevacizumab Biosimilar Granted FDA Approval for Several Cancer Types

The FDA approved bevacizumab-nwgd across several gastrointestinal, gynecological, brain, and lung cancer types.

FDA Approves Biocon’s Avastin Biosimilar

Jobevne is the fifth Avastin biosimilar, which are recombinant humanized monoclonal antibodies used to treat several different types of cancer.

FDA Approves Avastin Biosimilar Jobevne Across Several Cancer Types

The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.